procainamide

procainamide
Drug name	Procainamide
Routes of administration	Oral, intravenous, intramuscular
Metabolism	Hepatic, renal
Excretion	Renal
Cas number	51-35-4
Atc prefix	C01
Atc suffix	BA02

procainamide

Procainamide is a synthetic antiarrhythmic agent in the class of drugs historically derived from the dye chemistry era and introduced during the 20th century. It has been used to treat a range of atrial and ventricular arrhythmias and has influenced later developments in cardiovascular pharmacotherapy. Major clinical guidelines and large trials informed its contemporary role, and it remains of interest in cardiology, pharmacology, and medical history.

Medical uses

Procainamide is indicated for acute suppression of ventricular tachycardia and for conversion of sustained monomorphic ventricular tachycardia to sinus rhythm in settings reflected in guideline documents from organizations such as American Heart Association, European Society of Cardiology, and World Health Organization. It has been used for wide‑complex tachycardias when ischemia related to events like Myocardial infarction is suspected, and for refractory supraventricular arrhythmias when agents recommended by committees such as the National Institute for Health and Care Excellence are unsuitable. In hospital practice guided by protocols from institutions like Mayo Clinic and Cleveland Clinic, procainamide is sometimes chosen during electrophysiology consultations or in perioperative management in centers such as Johns Hopkins Hospital.

Pharmacology

Procainamide exerts antiarrhythmic effects primarily through blockade of fast sodium channels in cardiac myocytes, altering action potential conduction and refractoriness as discussed in texts from institutions like Harvard Medical School and Oxford University Press. It reduces phase 0 depolarization and can prolong the QT interval, a phenomenon characterized in electrocardiography studies taught at Stanford University and University of Pennsylvania. Metabolism involves hepatic N‑acetylation yielding N‑acetylprocainamide (NAPA), a metabolite with differing electrophysiologic properties noted in biochemical research at laboratories such as Massachusetts Institute of Technology and Pasteur Institute. Renal excretion of parent drug and metabolites is impacted by renal dysfunction described in publications from National Kidney Foundation. Pharmacokinetic variability including fast and slow acetylator phenotypes was elucidated in pharmacogenetic work from groups associated with National Institutes of Health and University of Cambridge.

Adverse effects

Adverse effects range from common dose‑related manifestations such as hypotension and proarrhythmia (including torsades de pointes) to immunologic reactions including drug‑induced lupus erythematosus-like syndromes historically linked to epidemiologic reports from centers like Mayo Clinic and Centers for Disease Control and Prevention. Hematologic complications such as agranulocytosis and neutropenia were documented in case series reported in journals affiliated with The Lancet and New England Journal of Medicine. Gastrointestinal upset and neurologic symptoms have been collated in drug safety bulletins from agencies like Food and Drug Administration and European Medicines Agency. Monitoring recommendations echo those in practice guidelines from American College of Cardiology and specialty texts used at Cleveland Clinic Lerner College of Medicine.

Contraindications and interactions

Absolute and relative contraindications include known hypersensitivity reactions recorded in pharmacovigilance databases maintained by World Health Organization and Food and Drug Administration. Caution is advised with concomitant use of other QT‑prolonging agents highlighted in drug interaction compendia from publishers such as Elsevier and UpToDate, and with agents affecting renal elimination as discussed in guidance from National Institute for Health and Care Excellence. Interactions with inhibitors or inducers of hepatic acetylation pathways were characterized in studies associated with Imperial College London and Karolinska Institutet. Co‑management with anticoagulants or drugs used in acute coronary syndromes is coordinated in practice within centers like Massachusetts General Hospital and Guy's and St Thomas' NHS Foundation Trust.

History and society

Procainamide emerged from mid‑20th century medicinal chemistry following earlier discoveries involving dye derivatives and synthetic local anesthetics, with contributions by researchers in institutions such as University of Michigan and University of Illinois. Its clinical adoption paralleled cardiology developments at hospitals like Mount Sinai Hospital and influenced subsequent antiarrhythmic classification systems promulgated by committees affiliated with American Heart Association and European Society of Cardiology. Public health considerations, regulatory reviews, and prominent case reports in periodicals like The Lancet and New England Journal of Medicine shaped perceptions of benefit and risk during epochs that also saw the rise of landmark randomized trials exemplified by work at Duke University and Vanderbilt University Medical Center.

Formulations and administration

Procainamide is available in injectable formulations for intravenous and intramuscular use and in oral tablets for maintenance therapy; these preparations are produced by pharmaceutical manufacturers operating in markets regulated by agencies such as Food and Drug Administration and European Medicines Agency. Dosing regimens described in formularies from British National Formulary and institutional protocols at Johns Hopkins Hospital recommend weight‑based IV loading followed by infusion with monitoring in settings like cardiac care units at Cleveland Clinic and intensive care units described in training at Columbia University Irving Medical Center. Administration is accompanied by electrocardiographic and laboratory surveillance per guidance from professional bodies including American College of Cardiology and European Society of Cardiology.

Category:Antiarrhythmic agents